This study presents a novel surface modification approach aimed at enhancing the biomedical applications of Salmonella. By employing a facile surface engineering technique involving pH-responsive polyserotonin (PST) and self-activated DNAzyme, the immune clearance and non-specific colonization of Salmonella can be effectively mitigated. The PST coating exhibits the ability to disassemble in acidic tumor microenvironments, thereby facilitating the controlled release of Salmonella and DNAzyme, leading to improved therapeutic outcomes.
Bacteria-based microbial immunotherapy shows various unique properties for tumor therapy owing to their active tropism to tumor and multiple anti-tumor mechanisms. However, its clinical benefit is far from satisfactory, which is limited by rapid systemic clearance and neutrophils-mediated immune restriction to compromise the efficacy, as well as non-specific distribution to cause toxicity. To address all these limitations, herein we reported a polyserotonin (PST) coated Salmonella (Sal) with surface adsorption of DNAzyme (Dz)-functionalized MnO2 nanoparticles (DzMN) for tumor therapy. PST could facilely coat on Sal surface via oxidation and self-polymerization of its serotonin monomer, which enabled surface stealth to avoid rapid systemic clearance while maintaining the tumor homing effect. Upon targeting to tumor, the PST was degraded and exfoliated in response to acidic tumor microenvironment, thus liberating Sal to recover its anti-tumor activities. Meanwhile, the DzMN was also delivered into tumor via hitchhiking Sal, which could release Dz and Mn2+ after tumor cells internalization. The Dz was then activated by its cofactor of Mn2+ to cleave target PD-L1 mRNA, thus serving as a self-activated system for gene silencing. Combining Sal and Dz for immune activation and PD-L1 knockdown, respectively, anti-tumor immunotherapy was achieved with enhanced efficacy. Notably, PST coating could significantly decrease infection potential and non-specific colonization of Sal at normal organs, achieving high in vivo biosafety. This work addresses the key limitations of Sal for in vivo application via biomaterials modification, and provides a promising platform for better microbial immunotherapy.
Lina Guo, Hao Chen, Jinsong Ding, Pengfei Rong, Ming Sun, Wenhu Zhou*
How to cite:
L. Guo, H. Chen, J. Ding, P. Rong, M. Sun, W. Zhou, Exploration 2023, 20230017.